Six-amino acid ghrelin receptor agonist. Triggers pulsatile growth hormone release with mild appetite stimulation and modest cortisol/prolactin effects.
Earlier-generation GH secretagogue, predates ipamorelin. Stronger GH spike than ipamorelin but less selective — measurable cortisol/prolactin elevation in some users. Investigated diagnostically for GH deficiency; off-label use for body composition is grey-market common.
More side-effect profile than ipamorelin (cortisol, prolactin, hunger). Off-label use without IGF-1 monitoring carries long-term unknown.
D-Ala-D-2-Nal-Ala-Trp-D-Phe-Lys (5 aa with D-stereoisomers and unnatural residues).
Per-claim grading. Each claim is graded independently — same peptide, different claims can carry different grades.
External links to PubMed searches, ClinicalTrials.gov, and FDA materials. We do not host papers — we point at canonical sources.
Pre-filled with this compound's published dose range: 100-300 µg · 2-3x daily, subcutaneous
Calculator is a discussion tool. Verify reconstitution + dosing with a qualified provider. Stack is not a prescription source. Use sterile technique and inspect every vial.
Expected reclassification — PCAC review Feb 2027
FDA's Pharmacy Compounding Advisory Committee scheduled to review the second cohort of peptides removed from Category 2 in April 2026. Panel votes whether to add each to the official 503A bulks list.